Language:
English
繁體中文
Help
圖資館首頁
Login
Back
Switch To:
Labeled
|
MARC Mode
|
ISBD
SARS-CoV-2 spike protein convergent ...
~
Focosi, Daniele.
SARS-CoV-2 spike protein convergent evolutionimpact of virus variants on efficacy of COVID-19 therapeutics and vaccines /
Record Type:
Electronic resources : Monograph/item
Title/Author:
SARS-CoV-2 spike protein convergent evolutionby Daniele Focosi.
Reminder of title:
impact of virus variants on efficacy of COVID-19 therapeutics and vaccines /
Author:
Focosi, Daniele.
Published:
Cham :Springer International Publishing :2021.
Description:
xiii, 136 p. :ill., digital ;24 cm.
Contained By:
Springer Nature eBook
Subject:
COVID-19 (Disease)
Online resource:
https://doi.org/10.1007/978-3-030-87324-0
ISBN:
9783030873240$q(electronic bk.)
SARS-CoV-2 spike protein convergent evolutionimpact of virus variants on efficacy of COVID-19 therapeutics and vaccines /
Focosi, Daniele.
SARS-CoV-2 spike protein convergent evolution
impact of virus variants on efficacy of COVID-19 therapeutics and vaccines /[electronic resource] :by Daniele Focosi. - Cham :Springer International Publishing :2021. - xiii, 136 p. :ill., digital ;24 cm. - SpringerBriefs in microbiology,2191-5393. - SpringerBriefs in microbiology..
Chapter 1. Why the Spike protein is relevant for COVID19 therapeutics -- Chapter 2. SARS-CoV-2 variants -- Chapter 3. Conclusion.
This book reviews the current knowledge of the globally circulating SARS-CoV-2 variants, highlights their distinct genetic characteristics and associated conformational changes in the viral spike protein, and profoundly discusses the mechanisms of convergent evolution that led to the rise of these mutated strains at different geographic regions during the Covid-19 pandemic. Furthermore, the book explores how these variants do and may impact the efficacy of established neutralizing antibody-based (nAb) vaccines and therapeutics by analysing latest in vivo and in vitro clinical data. Finally, the author discusses ways on how nAb Covid-19 treatment derived immune escape of SARS-CoV-2 could be minimized in the future.
ISBN: 9783030873240$q(electronic bk.)
Standard No.: 10.1007/978-3-030-87324-0doiSubjects--Topical Terms:
877725
COVID-19 (Disease)
LC Class. No.: RA644.C67
Dewey Class. No.: 614.592414
National Library of Medicine Call No.: QW 168.5.C8
SARS-CoV-2 spike protein convergent evolutionimpact of virus variants on efficacy of COVID-19 therapeutics and vaccines /
LDR
:01992nmm a2200349 a 4500
001
610339
003
DE-He213
005
20211011061046.0
006
m d
007
cr nn 008maaau
008
220330s2021 sz s 0 eng d
020
$a
9783030873240$q(electronic bk.)
020
$a
9783030873233$q(paper)
024
7
$a
10.1007/978-3-030-87324-0
$2
doi
035
$a
978-3-030-87324-0
040
$a
GP
$c
GP
041
0
$a
eng
050
4
$a
RA644.C67
060
4
$a
QW 168.5.C8
072
7
$a
MMFM
$2
bicssc
072
7
$a
MED052000
$2
bisacsh
072
7
$a
MKFM
$2
thema
082
0 4
$a
614.592414
$2
23
090
$a
RA644.C67
$b
F652 2021
100
1
$a
Focosi, Daniele.
$3
762680
245
1 0
$a
SARS-CoV-2 spike protein convergent evolution
$h
[electronic resource] :
$b
impact of virus variants on efficacy of COVID-19 therapeutics and vaccines /
$c
by Daniele Focosi.
260
$a
Cham :
$b
Springer International Publishing :
$b
Imprint: Springer,
$c
2021.
300
$a
xiii, 136 p. :
$b
ill., digital ;
$c
24 cm.
490
1
$a
SpringerBriefs in microbiology,
$x
2191-5393
505
0
$a
Chapter 1. Why the Spike protein is relevant for COVID19 therapeutics -- Chapter 2. SARS-CoV-2 variants -- Chapter 3. Conclusion.
520
$a
This book reviews the current knowledge of the globally circulating SARS-CoV-2 variants, highlights their distinct genetic characteristics and associated conformational changes in the viral spike protein, and profoundly discusses the mechanisms of convergent evolution that led to the rise of these mutated strains at different geographic regions during the Covid-19 pandemic. Furthermore, the book explores how these variants do and may impact the efficacy of established neutralizing antibody-based (nAb) vaccines and therapeutics by analysing latest in vivo and in vitro clinical data. Finally, the author discusses ways on how nAb Covid-19 treatment derived immune escape of SARS-CoV-2 could be minimized in the future.
650
0
$a
COVID-19 (Disease)
$3
877725
650
0
$a
Medical virology.
$3
197566
650
1 4
$a
Virology.
$3
196498
650
2 4
$a
Immunology.
$3
189152
650
2 4
$a
Medical Microbiology.
$3
273931
650
2 4
$a
Microbial Genetics and Genomics.
$3
273651
710
2
$a
SpringerLink (Online service)
$3
273601
773
0
$t
Springer Nature eBook
830
0
$a
SpringerBriefs in microbiology.
$3
559438
856
4 0
$u
https://doi.org/10.1007/978-3-030-87324-0
950
$a
Biomedical and Life Sciences (SpringerNature-11642)
based on 0 review(s)
ALL
電子館藏
Items
1 records • Pages 1 •
1
Inventory Number
Location Name
Item Class
Material type
Call number
Usage Class
Loan Status
No. of reservations
Opac note
Attachments
000000206650
電子館藏
1圖書
電子書
EB RA644.C67 F652 2021 2021
一般使用(Normal)
On shelf
0
1 records • Pages 1 •
1
Multimedia
Multimedia file
https://doi.org/10.1007/978-3-030-87324-0
Reviews
Add a review
and share your thoughts with other readers
Export
pickup library
Processing
...
Change password
Login